65,437 trials
Depressive Disorder, Major
Primary: Number of Participants With 50 Percent Or Greater Reduction in the MADRS Score Over Time for the Quetiapine XR 150-300mg and Placebo 2 Arms/Groups Stratified by…
Gastroesophageal Reflux
Primary: The Primary Symptom of GERD in Chinese Outpatients in Gastroenterology Department — 19; 30; 42; 23 Participants
COPD
Primary: Sputum Inflammatory Cell Counts — 5.42; 3.89 millions cells/ ml — p=0.012
Ischemic Stroke
Primary: The Percentage of Change in Optical Cerebral Blood Flow (oCBF) During Bolus Normal Saline Compared to Baseline, as Measured by Diffuse Correlation Spectroscopy (DCS)…
Recurrent Glioblastoma or Other Glioma Subtypes
Primary: Progression Free Survival — 1.7 months
Healthy Skin
Primary: Relative 16S Abundance - Control Soap — 100; 74; 84; 100 Percentage of Baseline
Autistic Disorder · Autism Spectrum Disorder
Primary: Spatial Attention Baseline — 80.3; 43.0 Percent Correct
Diarrhea
Primary: Number of Pans With Presence of Visible Feces Inside the Pan — 282; 203; 83; 124 pans
Metastatic Colorectal Cancer · Metastatic Breast Cancer
Primary: Number of Participants With or Without Blood Pressure Increase as a Predictor of Progression Free Survival (PFS) — 19; 11; 6; 4 Participants — p=0.8166
Eating Disorders · Female Athlete Triad
Primary: Eating Disorder Examination Questionnaire (EDE-Q) — .98; 1.24; .54; .84 units on a scale
Hereditary Hemorrhagic Telangiectasia (HHT)
Primary: Epistaxis Using the Epistaxis Severity Score, Hematocrit, Hemoglobin and Serum Feritin Levels..
Acromegaly
Primary: Core Phase: Percentage of Participants With Mean GH < 1 g/L and IGF-1 < ULN at Week 36 by Previous Treatment and Overall — 14.6; 13.8; 15.1; 14.6 Percentage of…
Hemophilia A or B
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 7; 4; 6; 4 Participants
Severe Hemophilia A
Primary: Total Annualized Bleeding Rate (TABR) — 2.10 No. of BEs / year (ABR) — p=<0.0001
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants Hospitalised With Severe Exacerbation — 3074; 630 Participants